Dendritic cell vaccine strategies for renal cell carcinoma

Bibliography

• MOTZER RJ, BANDER NH, NANUS DM: Renal-cell carcinoma. N. Engl. J. Med. (1996) 335(12):865-875.
   PubMed Web of Science ®Google Scholar
• ROSENBERG SA, YANG JC, TOPALIAN SL et al.: Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2 [see comments]. JAMA (1994) 271:907-913.
   PubMed Web of Science ®Google Scholar
• STOERKEL SF: Classification of renal cell carcinoma based on morphologic and cytogenetic correlations. In: Biology of Renal Cell Carcinoma. Bukowski RM, Finke JH, Klein EA (Eds), Springer-Verlag, New York, USA (1995):3-12.
   Google Scholar
• STOERKEL S, KEYMER R, STEINBACH F et al.: Reaction patterns of tumor infiltrating lymphocytes in different renal cell carcinomas and oncocytomas. Prog. Clin. Biol. Res. (1992) 378:217-223.
   PubMedGoogle Scholar
• SCHLEYPEN JS, VON GELDERN M, WEISS EH et al.: Renal cell carcinoma-infiltrating natural killer cells express differential repertoires of activating and inhibitory receptors and are inhibited by specific HLA class I allotypes. Int. J. Cancer (2003) 106(6):905-912.
   PubMed Web of Science ®Google Scholar
• SCHLEYPEN JS, BAUR N, ROHRMANN K et al.: Cytotoxic markers and frequency predict functional capacity of natural killer cells infiltrating renal cell carcinoma. Clin. Cancer Res. (2006) 12:718-725.
   PubMed Web of Science ®Google Scholar
• THURNHER M, RADMAYR C, RAMONER R et al.: Human renal-cell carcinoma tissue contains dendritic cells. Int. J. Cancer (1996) 68(1):1-7.
   PubMed Web of Science ®Google Scholar
• TROY AJ, SUMMERS KL, DAVIDSON PJ et al.: Minimal recruitment and activation of dendritic cells within renal cell carcinoma. Clin. Cancer Res. (1998) 4(3):585-593.
   PubMed Web of Science ®Google Scholar
• SCHENDEL DJ, OBERNEDER R, FALK CS et al.: Cellular and molecular analyses of major histocompatibility complex (MHC) restricted and non-MHC-restricted effector cells recognizing renal cell carcinomas: problems and perspectives for immunotherapy. J. Mol. Med. (1997) 75(6):400-413.
   PubMed Web of Science ®Google Scholar
• ANTONIA S, MULE JJ, WEBER JS: Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. (2004) 16(2):130-136.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: Immunotherapy: past, present and future. Curr. Opin. Immunol. (2003) 9(3):269-277.
   Google Scholar
• ZOU W: Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. (2006) 6:295-307.
   PubMed Web of Science ®Google Scholar
• FRANKENBERGER B, REGN S, GEIGER C et al.: Cell-based vaccines for renal cell carcinoma: genetically-engineered tumor cells and monocyte-derived dendritic cells. World J. Urol. (2005) 23(3):166-174.
   PubMed Web of Science ®Google Scholar
• STEINMAN RM, DHODAPKAR M: Active immunization against cancer with dendritic cells: the near future. Int. J. Cancer (2001) 94(4):459-473.
   PubMed Web of Science ®Google Scholar
• SCHULER G, SCHULER-THURNER B, STEINMAN RM: The use of dendritic cells in cancer immunotherapy. Curr. Opin. Immunol. (2003) 15(2):138-147.
   PubMed Web of Science ®Google Scholar
• JONULEIT H, KUHN U, MULLER G et al.: Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. (1997) 27:3135-3142.
   PubMed Web of Science ®Google Scholar
• MAILLIARD RB, WANKOWICZ-KALINSKA A, CAI Q et al.: Alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. (2004) 64:5934-5937.
   PubMed Web of Science ®Google Scholar
• NAPOLITANI G, RINALDI A, BERTONI F et al.: Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat. Immunol. (2005) 6:769-776.
   PubMed Web of Science ®Google Scholar
• PRINS RM, CRAFT N, BRUHN KW et al.: The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity. J. Immunol. (2006) 176:157-164.
   PubMed Web of Science ®Google Scholar
• YOUNG AN, AMIN MB, MORENO CS et al.: Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am. J. Pathol. (2001) 158(5):1639-1651.
   PubMed Web of Science ®Google Scholar
• STEVANOVIC S: Identification of tumour-associated T-cell epitopes for vaccine development. Nat. Rev. Cancer (2002) 2(7):514-520.
   PubMed Web of Science ®Google Scholar
• KIM HL, SELIGSON D, LIU X et al.: Using protein expressions to predict survival in clear cell renal carcinoma. Clin. Cancer Res. (2004) 10(16):5464-5471.
   PubMed Web of Science ®Google Scholar
• LAM JS, BELLDEGRUN AS, FIGLIN RA: Tissue array-based predictions of pathobiology, prognosis, and response to treatment for renal cell carcinoma therapy. Clin. Cancer Res. (2004) 15(10):6304-6309.
   Web of Science ®Google Scholar
• KRUGER T, SCHOOR O, LEMMEL C et al.: Lessons to be learned from primary renal cell carcinomas: novel tumor antigens and HLA ligands for immunotherapy. Cancer Immunol. Immunother. (2005) 54(9):826-836.
   PubMed Web of Science ®Google Scholar
• SULTMANN H, VON HEYDEBRECK A, HUBER W et al.: Gene expression in kidney cancer is associated with cytogenetic abnormalities, metastasis formation, and patient survival. Clin. Cancer Res. (2005) 15(1):646-655.
   Google Scholar
• BROSSART P, STUHLER G, FLAD T et al.: Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. Cancer Res. (1998) 58(4):732-736.
   PubMed Web of Science ®Google Scholar
• MULDERS P, TSO CL, GITLITZ B et al.: Presentation of renal tumor antigens by human dendritic cells activates tumor-infiltrating lymphocytes against autologous tumor: implications for live kidney cancer vaccines. Clin. Cancer Res. (1999) 5(2):445-454.
   PubMed Web of Science ®Google Scholar
• HEISER A, MAURICE MA, YANCEY DR et al.: Human dendritic cells transfected with renal tumor RNA stimulate polyclonal T-cell responses against antigens expressed by primary and metastatic tumors. Cancer Res. (2001) 61(8):3388-3393.
   PubMed Web of Science ®Google Scholar
• KUROKAWA T, OELKE M, MACKENSEN A: Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int. J. Cancer (2001) 91(6):749-756.
   PubMed Web of Science ®Google Scholar
• AVIGAN D: Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res. (2004) 10:6347-6352.
   PubMed Web of Science ®Google Scholar
• KUGLER A, STUHLER G, WALDEN P et al.: Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids [see comments]. Curr. Opin. Immunol. (2000) 6(3):332-333 [KUGLER A, STUHLER G, WALDEN P et al.: Retraction: regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Curr. Opin. Immunol. (2003) 9(9):1221].
   Google Scholar
• AVIGAN D, VASIR B, GONG J et al.: Fusion cell vaccination of patients with metastatic breast and renal cell cancer induces immunological and clinical responses. Clin. Cancer Res. (2004) 10:4699-708.
   PubMed Web of Science ®Google Scholar
• MARTEN A, RENOTH S, HEINICKE T et al.: Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. (2003) 14(5):483-494.
   PubMed Web of Science ®Google Scholar
• BARBUTO JA, ENSINA LF, NEVES AR et al.: Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. (2004) 53(12):1111-1118.
   PubMed Web of Science ®Google Scholar
• OOSTERWIJK-WAKKA JC, TIEMESSEN DM, BLEUMER I et al.: Vaccination of patients with metastatic renal cell carcinoma with autologous dendritic cells pulsed with autologous tumor antigens in combination with interleukin-2: a Phase I study. J. Immunother. (2002) 25(6):500-508.
   PubMed Web of Science ®Google Scholar
• AZUMA T, HORIE S, TOMITA K et al.: Dendritic cells immnotherapy for patients with metastatic renal cell carcinoma: University of Tokyo experience. Int. J. Urol. (2002) 9:340-346.
   PubMed Web of Science ®Google Scholar
• GITLITZ BJ, BELLDEGRUN AS, ZISMAN A et al.: A pilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. J. Immunother. (2003) 26(5):412-419.
   PubMed Web of Science ®Google Scholar
• PANDHA HS, JOHN RJ, HUTCHINSON J et al.: Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumour lysate-pulsed cells: a Phase I/II study. BJU Int. (2004) 94(3):412-418.
   PubMed Web of Science ®Google Scholar
• GRANUCCI F, ZANONI I, FEAU S et al.: Dendritic cell regulation of immune responses: a new role for interleukin 2 at the intersection of innate and adaptive immunity. EMBO J. (2003) 22(11):2546-2551.
   PubMed Web of Science ®Google Scholar
• MARTEN A, FLIEGER D, RENOTH S et al.: Therapeutic vaccination against metastatic renal cell carcinoma by autologous dendritic cells: preclinical results and outcome of a first clinical Phase I/II trial. Cancer Immunol. Immunother. (2002) 51(11-12):637-644.
   PubMed Web of Science ®Google Scholar
• HOLTL L, RIESER C, PAPESH C et al.: Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J. Urol. (1999) 161(3):777-782.
   PubMed Web of Science ®Google Scholar
• HOLTL L, ZELLE-RIESER C, GANDER H et al.: Immunotherapy of metastatic renal cell carcinoma with tumor lysate-pulsed autologous dendritic cells. Clin. Cancer Res. (2002) 8(11):3369-3376.
   PubMed Web of Science ®Google Scholar
• ARROYO JC, GABILONDO F, LORENTE L et al.: Immune response induced in vitro by CD16- and CD16+ monocyte-derived dendritic cells in patients with metastatis renal cell carcinoma treated with dendritic cell vaccines. J. Clin. Immunol. (2004) 24(1):86-96.
   PubMed Web of Science ®Google Scholar
• HOLTL L, RAMONER R, ZELLE-RIESER C et al.: Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol. Immunother. (2005) 54(7):663-670.
   PubMed Web of Science ®Google Scholar
• GRUNEBACH F, MULLER MR, NENCIONI A et al.: Delivery of tumor-derived RNA for the induction of cytotoxic T-lymphocytes. Gene Ther. (2003) 10(5):367-374.
   PubMed Web of Science ®Google Scholar
• SU Z, DANNULL J, HEISER A et al.: Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. Cancer Res. (2003) 63(9):2127-2133.
   PubMed Web of Science ®Google Scholar
• DANNULL J, SU Z, RIZZIERI D et al.: Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest. (2005) 115(12):3623-3633.
   PubMed Web of Science ®Google Scholar
• WEINSCHENK T, GOUTTEFANGEAS C, SCHIRLE M et al.: Integrated functional genomics approach for the design of patient-individual antitumor vaccines. Cancer Res. (2002) 62(20):5818-5827.
   PubMed Web of Science ®Google Scholar
• WIERECKY J, MÜLLER MR, WIRTHS S et al.: Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cell cancer patients. Cancer Res. (2006) 66(11):5910-5918.
   PubMed Web of Science ®Google Scholar
• FALK CS, NOESSNER E, WEISS EH et al.: Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Cancer Res. (2002) 62(2):480-487.
   PubMed Web of Science ®Google Scholar
• VON GELDERN M, SIMM B, BRAUN M et al.: TCR-independent cytokine stimulation induces non-MHC-restricted cell activity and is negatively regulated by HLA class I. Eur. J. Immunol. (2006) 36(9):2347-2358.
   PubMed Web of Science ®Google Scholar
• KALINSKI P, HILKENS CM, SNIJDERS A et al.: IL-12-deficient dendritic cells, generated in the presence of prostaglandin E2, promote type 2 cytokine production in maturing human naive T helper cells. J. Immunol. (1997) 159(1):28-35.
   PubMed Web of Science ®Google Scholar
• FEAU S, FACCHINETTI V, GRANUCCI F et al.: Dendritic cell-derived IL-2 production is regulated by IL-15 in humans and in mice. Blood (2005) 105(2):697-702.
   PubMed Web of Science ®Google Scholar
• HILKENS CM, KALINSKI P, DE BOER M et al.: Human dendritic cells require exogenous interleukin-12-inducing factors to direct the development of naive T-helper cells toward the Th1 phenotype. Blood (1997) 90(5):1920-1926.
   PubMed Web of Science ®Google Scholar
• SCHEFFER SR, NAVE H, KORANGY F et al.: Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo. Int. J. Cancer (2003) 103(2):205-211.
   PubMed Web of Science ®Google Scholar
• JAVOROVIC M, POHLA H, FRANKENBERGER B et al.: RNA transfer by electroporation into mature dendritic cells leading to reactivation of effector-memory cytotoxic T lymphocytes: a quantitative analysis. Mol. Ther. (2005) 12(4):734-743.
   PubMed Web of Science ®Google Scholar
• BONEHILL A, HEIRMAN C, TUYAERTS S et al.: Messenger RNA-electroporated dendritic cells presenting MAGE-A3 simultaneously in HLA class I and class II molecules. J. Immunol (2004) 172(11):6649-6657.
   PubMed Web of Science ®Google Scholar
• DULLAERS M, BRECKPOT K, VAN MEIRVENNE S et al.: Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols. Mol. Ther. (2004) 10(4):768-779.
   PubMed Web of Science ®Google Scholar
• LIAO X, LI Y, BONINI C et al.: Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol. Ther. (2004) 9(5):757-764.
   PubMed Web of Science ®Google Scholar
• CELLA M, ENGERING A, PINET V et al.: Inflammatory stimuli induce accumulation of MHC class II complexes on dendritic cells [see comments]. Nature (1997) 388(6644):782-787.
   PubMed Web of Science ®Google Scholar
• INABA K, TURLEY S, IYODA T et al.: The formation of immunogenic major histocompatibility complex class II-peptide ligands in lysosomal compartments of dendritic cells is regulated by inflammatory stimuli. J. Exp. Med. (2000) 191(6):927-936.
   PubMed Web of Science ®Google Scholar
• GILBOA E, VIEWEG J: Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. (2004) 199:251-263.
   PubMed Web of Science ®Google Scholar
• BERNTSEN A, GEERTSEN PF, SVANE IM: Therapeutic dendritic cell vaccination of patients with renal cell carcinoma. Eur. Urol. (2006) 50:34-43.
   PubMed Web of Science ®Google Scholar
• JAGER E, JAGER D, KNUTH A: Clinical cancer vaccine trials. Curr. Opin. Immunol. (2002) 14(2):178-182.
   PubMed Web of Science ®Google Scholar
• GEIGER C, REGN S, WEINZIERL A et al.: A generic RNA-pulsed dendritic cell vaccine strategy for renal cell carcinoma. J. Transl. Med. (2005) 26(39):29-43.
   Web of Science ®Google Scholar
• OVERWIJK WW: Breaking tolerance in cancer immunotherapy: time to ACT. Curr. Opin. Immunol. (2005) 17(2):187-194.
   PubMed Web of Science ®Google Scholar
• PHAN GQ, YANG JC, SHERRY RM et al.: Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA (2003) 100(14):8372-8377.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, ROSENBERG SA: Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat. Rev. Cancer (2003) 3(9):666-675.
   PubMed Web of Science ®Google Scholar
• DUDLEY ME, WUNDERLICH JR, ROBBINS PF et al.: Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science (2002) 298(5594):850-854.
   PubMed Web of Science ®Google Scholar
• CHILDS R, CHERNOFF A, CONTENTIN N et al.: Regression of metastatic renal-cell carcinoma after nonmyeloablative allogeneic peripheral-blood stem-cell transplantation [see comments]. N. Engl. J. Med. (2000) 343(11):750-758.
   PubMed Web of Science ®Google Scholar
• PATEL PH, CHAGANTI RS, MOTZER RJ: Targeted therapy for metastatic renal cell carcinoma. Br. J. Cancer (2006) 94(5):614-619.
   PubMed Web of Science ®Google Scholar
• RINI BI: VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices. Curr. Oncol. Rep. (2006) 8(2):85-89.
   PubMedGoogle Scholar
• VOGELZANG NJ: Treatment options in metastatic renal carcinoma: an embarrassment of riches. J. Clin. Oncol. (2006) 24(1):1-3.
   PubMed Web of Science ®Google Scholar
• BELARDELLI F, FERRANTINI M, PARMIANI G et al.: International meeting on cancer vaccines: how can we enhance efficacy of therapeutic vaccines? Cancer Res. (2004) 64(18):6827-6830.
   PubMedGoogle Scholar
• JANTZER P, SCHENDEL DJ: Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res. (1998) 58(14):3078-3086.
   PubMed Web of Science ®Google Scholar